Company Filing History:
3 out of 9 
1 out of 40 
1 out of 84 
Years Active: 2017-2021
Title: The Innovative Contributions of Andreas Zirlik
Introduction
Andreas Zirlik is a prominent inventor based in Freiburg, Germany. He has made significant contributions to the field of medical research, particularly in the area of inflammation and atherogenesis. With a total of three patents to his name, Zirlik's work has the potential to impact therapeutic approaches in these critical health areas.
Latest Patents
Zirlik's latest patents include groundbreaking inventions that focus on the selective targeting of the CD40L/Mac-1 interaction. One of his notable patents describes the use of small peptide inhibitors for the treatment of inflammation and atherogenesis. This invention highlights the potential of pharmaceutical compositions that comprise a polypeptide with the amino acid sequence EQLKKSKTL, along with antibodies that specifically bind to an epitope. Another significant patent involves the development of isolated monoclonal antibodies that bind to Mac-1, inhibit the interaction of CD40L with activated Mac-1, and do not induce integrin outside-in signaling.
Career Highlights
Throughout his career, Zirlik has worked with esteemed organizations such as the Baker IDI Heart and Diabetes Institute and Universitätsklinikum Freiburg. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to innovative research.
Collaborations
Zirlik has collaborated with notable professionals, including Dennis Wolf and Karlheinz Peter. These partnerships have further enhanced his research and development efforts in the medical field.
Conclusion
Andreas Zirlik's innovative work and patents in the field of inflammation and atherogenesis demonstrate his commitment to advancing medical science. His contributions have the potential to lead to significant improvements in treatment options for patients.